Articles dans des revues avec comité de lecture (71)
1.
Collet, L., Noël, J.-C., Catteau, X., Ardin, M., Berthet, J., Ghamry-Barrin, S., Treilleux, I., Bengrine Lefevre, L., Martinez, M., Rothé, F., Sotiriou, C., Caux, C., Dubois, B., Ray-Coquard, I., & Le Saux, O. (2025). Tumor-stroma proportion on primary tumor as a prognostic biomarker in advanced ovarian cancer patients receiving chemo-immunotherapy as first-line therapy: analyses from the NeoPembrOV/GINECO phase II randomized trial. ESMO Open, 10(6), 105104. doi:10.1016/j.esmoop.2025.1051042.
Blanc, J., Carnot, A., Barthélémy, P., Casert, V., Sautois, B., Van den Brande, J., Vanhaudenarde, V., Staudacher, L., Seront, E., Debien, V., Ameye, L., Kotecki, N., Rothé, F., Rorive, S., Fantoni, J. C., Tricard, T., Roumeguère, T., Awada, A., & Martinez Chanza, N. (2025). Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trial. Journal for ImmunoTherapy of Cancer, 13(5). doi:10.1136/jitc-2025-0120453.
Collet, L., Ardin, M., Venet, D., Berthet, J., Ghamry-Barrin, S., Treilleux, I., Noel, J.-C., Leheurteur, M., Meunier, J., Bengrine Lefevre, L., Martinez, M., Priou, F., Selle, F., Just, P. A., Bataillon, G., Rothé, F., Sotiriou, C., Caux, C., Dubois, B., Ray-Coquard, I., & Le Saux, O. (2025). Unravelling the tumor microenvironment and PD-L1 expression across tissue type in high-grade serous ovarian cancer in the NeoPembrOV/GINECO phase II randomized trial. Clinical cancer research. doi:10.1158/1078-0432.CCR-24-27124.
Rediti, M., Fimereli, D., Mileva, M., Wimana, Z., Venet, D., Flamen, P., Guiot, T., de Vries, E. E., Schröder, C. P., Menke-van der Houven van Oordt, W. C., Maetens, M. M., Majjaj, S., Larsimont, D., Rothé, F., Sotiriou, C., & Gebhart, G. (2025). Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial. Clinical cancer research, 31(1), 110-121. doi:10.1158/1078-0432.CCR-24-10075.
Rediti, M., Venet, D., Joaquin Garcia, A., Maetens, M. M., Vincent, D., Majjaj, S., El-abed, S., Di Cosimo, S., Ueno, T., Izquierdo, M., Piccart-Gebhart, M., Pusztai, L., Loi, S., Salgado, R., Viale, G., Rothé, F., & Sotiriou, C. (2024). Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial. Nature communications, 15(1), 10402. doi:10.1038/s41467-024-54621-36.
Wang, X., Venet, D., Lifrange, F., Larsimont, D., Rediti, M., Stenbeck, L., Dupont, F., Rouas, G., Garcia, A. J., Craciun, L., Buisseret, L., Ignatiadis, M., Carausu, M., Bhalla, N., Masarapu, Y., Villacampa, E. G., Franzén, L., Saarenpää, S., Kvastad, L., Thrane, K., Lundeberg, J., Rothé, F., & Sotiriou, C. (2024). Spatial transcriptomics reveals substantial heterogeneity in triple-negative breast cancer with potential clinical implications. Nature communications, 15(1), 10232. doi:10.1038/s41467-024-54145-w7.
Buisseret, L., Bareche, Y., Venet, D., Girard, E., Gombos, A., Emonts, P., Majjaj, S., Rouas, G., Serra, M., Debien, V., Agostinetto, E., Garaud, S., Willard-Gallo, K., Larsimont, D., Stagg, J., Rothé, F., & Sotiriou, C. (2024). The long and winding road to biomarkers for immunotherapy: a retrospective analysis of samples from patients with triple-negative breast cancer treated with pembrolizumab. ESMO Open, 9(5), 102964. doi:10.1016/j.esmoop.2024.1029648.
Buisseret, L., Loirat, D., Aftimos, P., Maurer, C., Punie, K., Debien, V., Kristanto, P., Eiger, D., Goncalves, A., Ghiringhelli, F., Taylor, D., Clatot, F., Van den Mooter, T., Ferrero, J. M., Bonnefoi, H., Canon, J.-L., Duhoux, F. P., Mansi, L., Poncin, R., Barthélémy, P., Isambert, N., Denis, Z., Catteau, X., Salgado, R., Agostinetto, E., de Azambuja, E., Rothé, F., Craciun, L., Venet, D., Romano, E., Stagg, J., Paesmans, M., Larsimont, D., Sotiriou, C., Ignatiadis, M., & Piccart-Gebhart, M. (2023). Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial. Nature communications, 14(1), 7018. doi:10.1038/s41467-023-42744-y9.
Rediti, M., Fernandez-Martinez, A., Venet, D., Rothé, F., Hoadley, K. A., Parker, J. S., Singh, B., Campbell, J. D., Ballman, K. V., Hillman, D. W., Winer, E. P., El-Abed, S., Piccart, M., Di Cosimo, S., Symmans, W. F., Krop, I., Salgado, R., Loi, S., Pusztai, L., Perou, C. M., Carey, L. A., & Sotiriou, C. (2023). Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials. Nature communications, 14(1), 7053. doi:10.1038/s41467-023-42635-210.
Joaquin Garcia, A., Rediti, M., Venet, D., Majjaj, S., Kammler, R., Munzone, E., Gianni, L., Thürlimann, B., Láng, I., Colleoni, M. A., Loi, S., Viale, G., Regan, M. M., Buisseret, L., Rothé, F., & Sotiriou, C. (2023). Differential benefit of metronomic chemotherapy among triple negative breast cancer subtypes treated in the IBCSG Trial 22-00. Clinical cancer research. doi:10.1158/1078-0432.CCR-23-126711.
Wang, X.-M., Collet, L., Rediti, M., Debien, V., De Caluwé, A., Venet, D., Romano, E., Rothé, F., Sotiriou, C., & Buisseret, L. (2023). Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges. Journal of Clinical Medicine, 12(3). doi:10.3390/jcm1203095312.
Bregni, G., Pretta, A., Senti, C., Acedo Reina, E., Vandeputte, C., Trevisi, E., Gkolfakis, P., Kehagias, P., Deleporte, A., Van Laethem, J.-L., Vergauwe, P., Van den Eynde, M., Deboever, G., Janssens, J., Demolin, G., Holbrechts, S., Clausse, M., De Grez, T., Peeters, M., D'Hondt, L., Geboes, K., Besse-Hammer, T., Rothé, F., Flamen, P., Hendlisz, A., & Sclafani, F. (2022). Circulating DNA in the neoadjuvant setting of early stage colon cancer. Acta oncologica, 61(10), 1223-1229. doi:10.1080/0284186X.2022.2101023